Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Brenda L Pennypacker"'
Autor:
Kenneth M. Kozloff, James Henderson, Brenda L Pennypacker, Isabel D. Colón-Bernal, Le T. Duong, Mark M. Banaszak Holl
Publikováno v:
Bone Reports, Vol 9, Iss, Pp 159-164 (2018)
Bone Reports
Bone Reports
Anti-resorptive drugs treat bone loss by blocking osteoclast activity through a variety of mechanisms of action. Once significant bone loss has occurred, the ability to restore biomechanical function may differ based on the drug chosen. To assess thi
Autor:
Le T. Duong, Thomas A Pearson, Pascal R. Buenzli, Brenda L Pennypacker, Keith R. Bambery, Mark J. Tobin, Christina Vrahnas, Natalie A. Sims
Publikováno v:
Calcified tissue international. 103(6)
Bone is formed by deposition of a collagen-containing matrix (osteoid) that hardens over time as mineral crystals accrue and are modified; this continues until bone remodeling renews that site. Pharmacological agents for osteoporosis differ in their
Autor:
Natalie A. Sims, Mark J. Tobin, Christina Vrahnas, Le T. Duong, Thomas A Pearson, Pascal R. Buenzli, Keith R. Bambery, Brenda L Pennypacker
Although cortical bone strength depends on optimal bone composition, the influences of standard therapeutic agents for osteoporosis on bone mineral accrual in cortical bone are not understood. This study compared effects on cortical bone composition
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::025b3bcb7875898d45871145e76eee69
https://doi.org/10.1101/255703
https://doi.org/10.1101/255703
Autor:
Donald B. Kimmel, David B. Gilberto, Nicholas T Gatto, Rana Samadfam, Brenda L Pennypacker, Le Thi Duong, Susan Y. Smith
Publikováno v:
Journal of Orthopaedic Research. 34:72-80
The effects of the cathepsin K inhibitor odanacatib (ODN) on fracture healing were monitored for ∼6 and 15 weeks post-fracture in two separate studies using the unilateral transverse mid-ulnar osteotomy model in skeletally mature female rabbits. Ra
Autor:
William J. Ray, Chang Bai, Stephen E. Alves, Tara E. Cusick, Brenda L Pennypacker, Evan E. Opas, Michael J. Chisamore, Carlo J. Gambone, Damien Ferraro, David J. Bettoun, Azriel Schmidt, Hilary A. Wilkinson, Angela Scafonas, Michael A. Gentile, Osvaldo A. Flores, Paul Hodor, Meissner Robert S, James J. Perkins
Publikováno v:
The Journal of Steroid Biochemistry and Molecular Biology. 143:29-39
Prostate cancer (PCa) initially responds to inhibition of androgen receptor (AR) signaling, but inevitably progresses to hormone ablation-resistant disease. Much effort is focused on optimizing this androgen deprivation strategy by improving hormone
Autor:
Mei-Shu Shih, Mary Belfast, Brenda L Pennypacker, Helen Zheng, Le T. Duong, Rana Samadfam, Charles Chen
Publikováno v:
Journal of Bone and Mineral Research. 29:1847-1858
Treatment with the cathepsin K (CatK) inhibitor odanacatib (ODN) protects against bone loss and maintains normal biomechanical properties in the spine and hip of ovariectomized (OVX) preclinical models. Here, we characterized the effects of ODN on th
Autor:
Jean-Marie Delaissé, Brenda L Pennypacker, Thomas Levin Andersen, Pia Rosgaard Jensen, Le T. Duong
Publikováno v:
Jensen, P R, Andersen, T L, Pennypacker, B L, Duong, L T & Delaissé, J-M 2014, ' The Bone Resorption Inhibitors Odanacatib and Alendronate Affect Post-Osteoclastic Events Differently in Ovariectomized Rabbits ', Calcified Tissue International, vol. 94, no. 2, pp. 212-222 . https://doi.org/10.1007/s00223-013-9800-0
Calcified Tissue International
Calcified Tissue International
Odanacatib (ODN) is a bone resorption inhibitor which differs from standard antiresorptives by its ability to reduce bone resorption without decreasing bone formation. What is the reason for this difference? In contrast with other antiresorptives, su
Autor:
Brenda L Pennypacker, Ya Zhuo, Susan Y. Smith, K. R. Scott, T. Cusick, Rana Samadfam, Le T. Duong, Charles Chen, Maureen Pickarski
Publikováno v:
Bone. 88
The objectives here were to evaluate the effects of odanacatib (ODN) at doses exceeding the clinical exposure on biomechanical properties of lumbar vertebrae (LV), hip and central femur (CF), and compare ODN to alendronate (ALN) on bone remodeling/mo
Autor:
Le T. Duong, Maureen Pickarski, Susan Y. Smith, P. Masarachia, Donald B. Kimmel, G Wesolowski, Brenda L Pennypacker, Boyd B. Scott, Rani Samadfam, Jason E. Goetzmann, K. R. Scott
Publikováno v:
Journal of Bone and Mineral Research. 27:509-523
Odanacatib (ODN) is a selective and reversible inhibitor of cathepsin K (CatK) currently being developed as a once-weekly treatment for osteoporosis. In this study, we evaluated the effects of ODN on bone turnover, bone mineral density (BMD), and bon
Autor:
Tara E. Cusick, Brenda L Pennypacker, Le T. Duong, Donald B. Kimmel, Boyd B. Scott, Charles M Chen, Maureen Pickarski
Publikováno v:
Journal of Bone and Mineral Research. 27:524-537
Odanacatib (ODN) is a selective and reversible inhibitor of cathepsin K (CatK). Previously, ODN was shown to increase bone mineral density (BMD) and maintained normal bone strength at the spine in ovariectomized (OVX) rhesus monkeys. Here, we further